Successful Switch of Patients with Rheumatoid Arthritis Developing Anti-tumor Necrosis Factor (anti-TNF)-induced Lupus to Another Anti-TNF Agent

Carrie Ye, D. Sholter, Liam Martin, Stephanie KeelingThe Journal of Rheumatology 2011 · DOI · OpenAlex

Introduction

Anti-tumor necrosis factor (anti-TNF) therapies have revolutionized the treatment of Rheumatoid Arthritis (RA). However, these potent biologics carry a rare but significant risk: anti-TNF-induced lupus (ATIL). ATIL is a form of drug-induced lupus where the immune system begins attacking the body's own tissues, mimicking Systemic Lupus Erythematosus (SLE).

Traditionally, the development of ATIL has mandated the immediate and permanent cessation of all TNF inhibitors. This clinical decision often leaves the patient’s underlying RA untreated, leading to debilitating flares. The hesitation to "switch" to another agent within the same class stems from a fear of a "class effect," where any TNF inhibitor might re-trigger the autoimmune response. This paper, published in The Journal of Rheumatology, provides critical evidence that ATIL may be drug-specific rather than class-specific, allowing for successful therapeutic transitions.

The Clinical Challenge: ATIL vs. Classic Drug-Induced Lupus

ATIL presents differently than classic drug-induced lupus (typically associated with medications like hydralazine). While classic cases often feature anti-histone antibodies, ATIL is characterized by a higher frequency of skin involvement and the presence of anti-dsDNA antibodies.

Because there were only eight documented cases of successful TNF inhibitor switching in the medical literature at the time of this report, rheumatologists faced a significant data gap. This study adds two detailed case reports to the evidence base, suggesting that the type of TNF inhibitor—monoclonal antibody versus fusion protein—matters significantly.

Case Presentations

The authors describe two female patients with long-standing seropositive RA who developed ATIL while on monoclonal antibody therapy.

Case 1

A 43-year-old woman achieved RA remission on adalimumab. However, following a dosage increase to manage an arthritis flare, she developed severe pleuritis (inflammation of the lung lining). Laboratory tests revealed new anti-dsDNA antibodies. After adalimumab was discontinued and her symptoms were managed with prednisone, she was switched to etanercept. She has now maintained RA remission for four years with no recurrence of lupus symptoms, and her anti-dsDNA antibodies have returned to negative.

Case 2

A 58-year-old woman treated with infliximab developed oral ulcers and joint synovitis. Following the diagnosis of ATIL, she was transitioned to etanercept. She has remained in RA control for two and a half years without a recurrence of lupus features or autoantibodies.

Key Insights: Immunogenicity and Class Switching

The success of these switches highlights a fundamental difference in the immunogenicity of anti-TNF agents:

  • Monoclonal Antibodies (Infliximab, Adalimumab): These agents appear more likely to induce anti-dsDNA antibodies, with some studies suggesting an incidence as high as 50%.
  • Soluble Receptor Fusion Proteins (Etanercept): This class appears less likely to trigger the specific autoimmune pathways leading to ATIL.
  • The Role of Biomarkers: One patient had pre-existing anti-SSA (Ro) antibodies. The authors suggest that patients with these antibodies may be at a higher baseline risk for developing ATIL, representing a subgroup with a closer immunological relationship to SLE.

Clinical Implications and Limitations

The core finding of this report is that ATIL is often a drug-specific reaction. A patient who reacts poorly to a monoclonal antibody may tolerate a fusion protein like etanercept perfectly well. This offers a vital pathway for maintaining RA remission in patients who would otherwise be forced to abandon a highly effective class of medication.

However, the authors note several caveats:

  1. Sample Size: These findings are based on a small case series (n=2) and require further validation through larger registry data.
  2. Monitoring: Switching agents requires rigorous clinical and serological follow-up to detect early signs of lupus recurrence.
  3. Severity: The decision to switch should be based on the severity of the initial ATIL reaction. Patients who experienced life-threatening organ involvement may not be suitable candidates for a class switch.

Conclusion

For clinicians managing RA, this report provides a precedent for "switching" rather than "stopping" in the face of ATIL. By transitioning from monoclonal antibodies to etanercept, it is possible to maintain disease control and protect the patient's long-term joint health without re-triggering induced lupus.

Summary updated

Abstract

To the Editor: We read with interest the recent letter1 and editorial2 discussing anti-tumor necrosis factor (anti-TNF)-induced lupus requiring cessation of therapy for disease resolution. A lack of published experience of successful TNF inhibitor switching (8 total cases in the literature) causes concern for rheumatologists faced with this clinical scenario. We describe 2 more patients who successfully switched to different TNF inhibitor after developing anti-TNF-induced lupus. A 43-year-old woman with a 15-year history of seropositive rheumatoid arthritis (RA) achieved remission when treated with adalimumab 50 mg biweekly 8 years ago. Adalimumab was increased to 50 mg weekly when she developed an arthritis flare. Her arthritis worsened and she developed severe pleuritis but no other lupus features. Laboratory investigations revealed anti-dsDNA antibodies that were not present in her preadalimumab antibody profile and persistence of anti-SSA antibodies that were present prior to adalimumab. A diagnosis of adalimumab-induced lupus was made and adalimumab was discontinued. Her symptoms resolved while taking prednisone … Address correspondence to Dr. Keeling; E-mail: stephanie.keeling{at}ualberta.ca
BibTeX
@article{ye2011successful,
  author = {Carrie Ye and D. Sholter and Liam Martin and Stephanie Keeling},
  title = {{Successful Switch of Patients with Rheumatoid Arthritis Developing Anti-tumor Necrosis Factor (anti-TNF)-induced Lupus to Another Anti-TNF Agent}},
  journal = {The Journal of Rheumatology},
  year = {2011},
  doi = {10.3899/jrheum.100830},
}
Figure